InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.037 -0.027 (-42.19%)+
Announcement
Release
30 Oct 2025 9:52AM
Price at Release
$0.064
Full Release
download
Summary
Firebrick Pharma Limited has announced the upcoming launch of Nasodine Throat Spray, the first new product in the Nasodine range since the Nasal Spray. This 1.0% povidone-iodine antiseptic formulation aims to treat sore throats conveniently without the need for gargling. The manufacturing process commences in November 2025 for export to Singapore, the initial market where it will launch in December 2025. The product will initially target hospitals and healthcare professionals, with an anticipated retail availability by mid-2026.
Key Points
  • Firebrick Pharma Limited (ASX:FRE) announces the manufacture of Nasodine Throat Spray set to begin for export in November 2025.
  • Nasodine Throat Spray is a 1.0% povidone-iodine formulation to treat sore throats in a spray form.
  • The Throat Spray will first be launched in Singapore in December 2025.
  • The product will be marketed initially to Singapore hospitals and doctors and is expected to be available in retail mid-2026.
  • Nasodine Throat Spray follows the Nasodine Nasal Spray and signifies future Nasodine-brand products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.